KeyBanc upgraded Acadia Healthcare to Overweight from Sector Weight with a $70 price target. The stock “could inflect meaningfully higher” during 2025, as investors gain visibility into the potential 2026 EBITDA acceleration, the analyst tells investors in a research note. The firm says the company’s 2026 EBITDA will benefit from the maturation of 2024-2025 bed adds and moderating startup costs. KeyBanc believes Acadia ‘s valuation “can begin to normalize” during 2025 as negative press headlines from 2024 fade and 2026 EBITDA comes into focus.
previous post